Substance-Related Disorders Clinical Trial
Official title:
Doxazosin as a Potential Treatment for Methamphetamine Dependence
The purpose of the study is to asses the potential interactions between methamphetamine and
doxazosin in methamphetamine-dependent volunteers who are not seeking treatment. The study
will evaluate the effects of doxazosin on the cardiovascular and subjective effects of
methamphetamine in a human laboratory study.
The primary objective is to determine the safety of treatment with doxazosin in
methamphetamine-dependent volunteers by examining hemodynamic and subjective effects of
administration of ascending doses of methamphetamine and a placebo dose during treatment
with doxazosin.
The secondary objective is to determine effects of treatment with doxazosin, as compared to
placebo, on subjective effects produced by administration of methamphetamine or placebo
Purpose:
To determine the effects of treatment with doxazosin, compared to treatment with placebo, on
methamphetamine-induced craving and subjective effects in methamphetamine-dependent human
volunteers.
Secondary aims are to clarify the genetics of substance abuse, potentially leading to
improved methods to diagnosis those at risk and to help develop better therapeutic
interventions and to develop a new saliva-based test for the detection and measurement of
drugs of abuse.
Design/Procedure:
Twenty non-treatment-seeking methamphetamine-dependent volunteers will complete procedures
during treatment with placebo and study medication, in random order, using a
within-subjects, double-blind, placebo-controlled design. There will be a two week period
between each phase. The dose of doxazosin needed to alter the effects of methamphetamine is
unknown and preclinical animal studies have not been conducted. Because of this, initially
the investigators will study the effects of a low dose of doxazosin (4mg daily) compared to
placebo daily. Methamphetamine (0, 10, and 30mg, smoked) will be administered during
treatment with 4mg doxazosin/placebo. Methamphetamine will be administered in ascending dose
(10mg followed by 20mg) with the 0mg dose randomly interspersed to maintain the blind.
Cardiovascular measures and subjective effects ratings will be assessed following
methamphetamine administration.
Participants will be monitored for stability on days 11 and 12 and discharged from the
hospital on day 13.
If 4mg doxazosin treatment is well tolerated but is not associated with alterations in the
effects of methamphetamine, a second group of subjects will be studied using the same sample
size. Treatment will begin at 1mg and increased by 1mg increments every three days until 8mg
is reached. Placebo will be dosed identically. All study procedures will be identical as
described above.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver)
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05054738 -
CRP and S&A for Inpatient Veterans
|
N/A | |
Recruiting |
NCT04157062 -
An Open-Label Trial of Repetitive Transcranial Magnetic Stimulation for Opioid Use Disorder
|
N/A | |
Completed |
NCT02233738 -
Group Motivational Interviewing (GMI) For Homeless Veterans In VA Services
|
N/A | |
Enrolling by invitation |
NCT06084221 -
Fatal Overdose Review Teams - Research to Enhance Surveillance Systems
|
N/A | |
Completed |
NCT02907944 -
Working With HIV Clinics to Adopt Addiction Treatments Using Implementation Facilitation
|
N/A | |
Completed |
NCT02570360 -
Exercise and Treatment-as-usual in Substance Use Treatment Outcomes
|
N/A | |
Completed |
NCT02829970 -
Helping College Students With ADHD Lead Healthier Lifestyles
|
N/A | |
Completed |
NCT02945371 -
Tailored Inhibitory Control Training to Reverse EA-linked Deficits in Mid-life
|
N/A | |
Completed |
NCT02125539 -
Field Trial of a Relapse Prevention Program for Adolescents Receiving Substance Use Treatment
|
Phase 2 | |
Completed |
NCT02388243 -
The Computer-based Drug and Alcohol Training Assessment in Kenya
|
N/A | |
Completed |
NCT02715557 -
Arise: An Online Relapse Prevention Tool for Adolescent Substance Abusers
|
N/A | |
Completed |
NCT01633138 -
Performance-based Reinforcement to Enhance Cognitive Remediation Therapy
|
N/A | |
Completed |
NCT02218970 -
The Effect of Muscular Strength Training in Patients With Drug Addiction
|
N/A | |
Completed |
NCT01591239 -
Home-Based Program to Help Parents of Drug Abusing Adolescents
|
N/A | |
Active, not recruiting |
NCT01539525 -
Screening to Augment Referral to Treatment- Project START
|
Phase 2 | |
Withdrawn |
NCT01224002 -
A Comparative Feasibility Study to Assess the Prevalence and Severity of Dental Caries in Incarcerated People Who Abuse Methamphetamine
|
N/A | |
Withdrawn |
NCT00891631 -
Primary Care iSBIRT to Reduce Serious Teen Health Risks
|
Phase 1/Phase 2 | |
Completed |
NCT00970372 -
Dual-Diagnosis and Compulsory Treatment
|
N/A | |
Completed |
NCT01365247 -
Concurrent Treatment for Substance Dependent Individuals With Post-Traumatic Stress Disorder (PTSD)
|
N/A | |
Completed |
NCT00419029 -
Motivational Interviewing to Engage Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) Veterans in Mental Health Treatment
|
N/A |